Focus on cancer proteomics.
Proteomics Clin. Appl. 2013, 7, 315
Focus on Cancer Proteomics
O. John Semmes
Motivated by the ever increasing demands for improved analytical and computational capa-
bilities in support of proteomic research, technology has rocketed forward. As an example,
high-end mass spectrometry touts a competitive half-life on par with Moore’s law in the com-
puter industry. Every few years we can expect significant technical improvement in the tools
applied to this rapidly growing field. Although it is often easy to become enamored by these
technological advances, it is critical that these do not distract from the equally important ac-
tivities related to developing robust applications to maximize the biomedical impact of these
developmental cycles. The field of Cancer Proteomics is ultimately dependent upon develop-
Many of the assumptions used to develop improved technology do not resonate with the real-
ities of experimentation with clinical samples or complex models of disease. The objective of
this Focus Issue is to highlight successful efforts in the application of novel technologies for
cancer proteomic studies.
Included in this issue are four full-length articles and three technical notes that span a va-
riety of technology application. Morrissey et al. describe a robust approach for the application
of label-free LC-MS/MS-based quantitation of serum for the discovery of candidate protein
biomarkers of prostate cancer. The design is toward a pipeline from discovery within a clinical
trial cohort to a testable MRM-based assay. Chao et al., recognizing the important role of
the immune response in both disease development and treatment, describe an array-based
approach for profiling patient autoimmune responses. They detail an application of this tech-
nology to uncover an immunosuppressive effect of hormone therapy in breast cancer patients.
Longuespee et al. present a study that employs MALDI MS imaging to uncover molecular
events that potentially drive histopathologic etiology of serous ovarian cancer. In an attempt to
address the issue of low abundance tumor specific proteins, researchers may be able to resort
to the analysis of cell models. In this issue, Marimuthu et al. examine the secretome of gastric
tumor cell lines utilizing SILAC-based quantitation. Similarly, Roper et al. employed azido
sugar metabolic labeling to assist in the capture and quantitative analysis of the secretome in a
prostate cancer stromal cell model. Our series concludes with two articles describing techno-
1-Step human-coupled in vitro transcription/translation for the efficient expression of target
proteins in a mammalian IVT system. Wang et al., from the same group, describe a novel
approach to achieve expression and arraying of denatured proteins specifically targeted at the
identification of disease specific autoantibodies.
on overcoming barriers common to the field of clinical proteomics. We thank the authors for
their generous commitment of time and energy to make this Focus Issue a success!
O. John SemmesThomas Conrads
C ?2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim